ADAP

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).